Alzamend Neuro Reports Q3 Loss of $(0.58) EPS, Zero Revenue; Confirms Urgent Need for Capital
ALZN sits 41% above its 52-week low of $1.58.
Summary
Alzamend Neuro, a nano-cap clinical-stage biotech, reported its Q3 financial results, showing no product revenue and a net loss of $(0.58) per share for the quarter and $(1.89) per share year-to-date. The company posted a net loss of $(2.20) million for the quarter and $(5.90) million year-to-date. These results underscore the company's significant cash burn and its explicit statement in the filing that "expansion of clinical programs and ongoing trial execution will require additional capital raises to sustain development plans." This financial update provides critical context for the recent At-The-Market (ATM) offering of up to $3.0 million initiated on March 6th, and the proposed reverse stock split on February 26th, both aimed at addressing the company's financial needs and Nasdaq listing compliance. Traders will be closely watching for updates on capital raises and the topline data from the AL001 Phase IIb trial, expected in Q1 2026, as key catalysts.
At the time of this announcement, ALZN was trading at $2.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $1.58 to $10.17. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.